Nemaura Medical Inc. (NMRD)
USD 0.0
(-50.0%)
USD 0.0
(-50.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 7.13 Million USD | -7.65% |
| 2022 | 7.73 Million USD | 68.53% |
| 2021 | 4.58 Million USD | -4.01% |
| 2020 | 4.77 Million USD | 6.74% |
| 2019 | 4.47 Million USD | 134.51% |
| 2018 | 1.9 Million USD | 23.06% |
| 2017 | 1.55 Million USD | 0.76% |
| 2016 | 1.53 Million USD | 16.65% |
| 2015 | 1.31 Million USD | 125.14% |
| 2014 | 586.23 Thousand USD | -29.42% |
| 2013 | 830.57 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 2.05 Million USD | 12.56% |
| 2024 Q3 | 1.54 Million USD | -24.84% |
| 2024 Q2 | 2.05 Million USD | -0.37% |
| 2023 Q2 | 1.62 Million USD | -26.45% |
| 2023 FY | 7.13 Million USD | -7.65% |
| 2023 Q4 | 1.82 Million USD | 188.71% |
| 2023 Q3 | 633.37 Thousand USD | -61.05% |
| 2023 Q1 | 2.21 Million USD | -14.66% |
| 2022 Q4 | 2.59 Million USD | 43.65% |
| 2022 Q1 | 1.62 Million USD | 17.49% |
| 2022 Q2 | 1.71 Million USD | 5.81% |
| 2022 Q3 | 1.8 Million USD | 5.18% |
| 2022 FY | 7.73 Million USD | 68.53% |
| 2021 Q3 | 1.06 Million USD | -12.98% |
| 2021 FY | 4.58 Million USD | -4.01% |
| 2021 Q4 | 1.37 Million USD | 29.1% |
| 2021 Q1 | 911.03 Thousand USD | -32.36% |
| 2021 Q2 | 1.22 Million USD | 34.77% |
| 2020 Q2 | 1.11 Million USD | -11.01% |
| 2020 Q1 | 1.25 Million USD | -22.73% |
| 2020 FY | 4.77 Million USD | 6.74% |
| 2020 Q4 | 1.34 Million USD | 27.14% |
| 2020 Q3 | 1.05 Million USD | -5.16% |
| 2019 Q1 | 771.96 Thousand USD | 35.96% |
| 2019 FY | 4.47 Million USD | 134.51% |
| 2019 Q4 | 1.62 Million USD | 74.13% |
| 2019 Q3 | 932.92 Thousand USD | -18.69% |
| 2019 Q2 | 1.14 Million USD | 48.63% |
| 2018 Q4 | 567.77 Thousand USD | 19.19% |
| 2018 Q3 | 476.35 Thousand USD | 6.44% |
| 2018 Q2 | 447.51 Thousand USD | 7.24% |
| 2018 Q1 | 417.32 Thousand USD | 16.17% |
| 2018 FY | 1.9 Million USD | 23.06% |
| 2017 FY | 1.55 Million USD | 0.76% |
| 2017 Q4 | 359.23 Thousand USD | -4.3% |
| 2017 Q3 | 375.36 Thousand USD | 16.4% |
| 2017 Q2 | 322.48 Thousand USD | -34.74% |
| 2017 Q1 | 494.18 Thousand USD | 18.31% |
| 2016 Q1 | 402.82 Thousand USD | -24.84% |
| 2016 FY | 1.53 Million USD | 16.65% |
| 2016 Q4 | 417.71 Thousand USD | 27.05% |
| 2016 Q3 | 328.78 Thousand USD | -15.76% |
| 2016 Q2 | 390.3 Thousand USD | -3.11% |
| 2015 Q4 | 535.93 Thousand USD | 237.57% |
| 2015 FY | 1.31 Million USD | 125.14% |
| 2015 Q1 | 269.25 Thousand USD | 66.07% |
| 2015 Q2 | 355.88 Thousand USD | 32.18% |
| 2015 Q3 | 158.76 Thousand USD | -55.39% |
| 2014 Q1 | 61.77 Thousand USD | -70.25% |
| 2014 Q3 | 340.19 Thousand USD | 1437.12% |
| 2014 Q4 | 162.12 Thousand USD | -52.34% |
| 2014 FY | 586.23 Thousand USD | -29.42% |
| 2014 Q2 | 22.13 Thousand USD | -64.17% |
| 2013 Q4 | 207.64 Thousand USD | 0.0% |
| 2013 FY | 830.57 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acutus Medical, Inc. | 11.22 Million USD | 36.397% |
| Biotricity, Inc. | 17.18 Million USD | 58.458% |
| Cell MedX Corp. | 313.43 Thousand USD | -2177.639% |
| Dynatronics Corporation | 9.9 Million USD | 27.949% |
| PetVivo Holdings, Inc. | 11.36 Million USD | 37.163% |
| RetinalGenix Technologies Inc. | 2.08 Million USD | -242.052% |
| Sonendo, Inc. | 68.46 Million USD | 89.573% |
| Telesis Bio, Inc. | 63.48 Million USD | 88.756% |
| Talis Biomedical Corporation | 67.18 Million USD | 89.375% |
| Viveve Medical, Inc. | 22.17 Million USD | 67.804% |